Table 2 Details of aGvHD grade and treatment prior to MSC-FFM therapy by age group
Children < 18 years (n = 33) | Adults ≥ 18 years (n = 123) | Overall (N = 156) | ||
|---|---|---|---|---|
aGvHD Grade, n (%) | ||||
II | 2 (6.1%) | 6 (4.9%) | 8 (5.1%) | |
III | 10 (30.3%) | 52 (42.3%) | 62 (39.7%) | |
IV | 21 (63.6%) | 63 (51.2%) | 84 (53.8%) | |
Missing | 0 (0.0%) | 2 (1.6%) | 2 (1.3%) | |
Prior aGvHD therapies, n (%) Number | ||||
1 | 0 (0.0%) | 1 (0.8%) | 1 (0.6%) | |
> 1 | 33 (100.0%) | 122 (99.2%) | 155 (99.4%) | |
Median | 7.0 | 4.0 | 4.0 | |
Min, max | 2, 11 | 1, 10 | 1, 11 | |
Time from last HSCT to first MSC-FFM administration, days | ||||
n | 32 | 123 | 155 | |
Mean (SD) | 105.7 (80.4) | 141.6 (110.4) | 134.2 (105.7) | |
Median (Q1, Q3) | 83.0 (50.0, 137.0) | 112.0 (69.0, 181.0) | 106.0 (64.0, 174.0) | |
Min, Max | 30, 346 | 17, 671 | 17, 671 | |
Missing | 1 | 0 | 1 | |